extfieldsofstudy: Medicine Chemistry

s2fieldsofstudy: Biology Medicine

text:
Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives.

Cranberry juice is a popular beverage with many health benefits. It has anthocyanins to supplement dietary needs. Based on in vitro evidence cranberry juice is an inhibitor of CYP enzymes and at higher amounts as potent as ketoconazole (CYP3A) and fluconazole (CYP2C9). There is, however, a discrepancy between in vitro and in vivo observations with respect to a number of substrates (cyclosporine, warfarin, flurbiprofen, tizanidine, diclofenac, amoxicillin, ceflacor); with the exception of a single report on midazolam, where there was a moderate increase in the AUC of midazolam in subjects pre-treated with cranberry juice. However, another study questions the clinical relevancy of in vivo pharmacokinetic interaction between cranberry juice and midazolam. The controversy may be due to a) under in vitro conditions all anthocyanin principles may be available to have a concerted effort in CYP inhibition; however, limited anthocyanin principles may be bioavailable with varying low levels in the in vivo studies; b) a faster clearance of the active anthocyanin principles under in vivo conditions may occur, leading to low threshold levels for CYP inhibition; c) efficient protein binding and/or rapid tissue uptake of the substrate may have precluded the drug availability to the enzymes in the in vivo studies. With respect to pharmacodynamic aspects, while the debate continues on the issue of an interaction between warfarin and cranberry juice, the summation of the pharmacodynamics data obtained in patients and healthy subjects from different prospectively designed and controlled clinical trials does not provide overwhelming support for the existence of a pharmacodynamic drug interaction for normal cranberry juice ingestion. However, it is apparent that consumption of large quantities of cranberry juice (about 1-2 L per day) or cranberry juice concentrates in supplements for an extended time period (>3-4 weeks) may temporally alter the effect of warfarin. Therefore, the total avoidance of cranberry juice by warfarin users may not be warranted by the published studies. However, in certain situations of higher intake of cranberry juice or concentrate there may be a need to monitor both warfarin doses and its effect.

INTRODUCTION
The concept of health drinks has developed rapidly across the globe with the rapid emergence of several fruit juices with promising evidence for numerous therapeutic benefits. One such popular fruit beverage is cranberry juice, whose beneficial effects in preventing bacterial infections especially in urinary tract are well established (1)(2)(3)(4). Cranberry juice has been extensively studied for numerous other therapeutic benefits ranging from diabetes, metabolic syndrome, obesity, prevention of risks of cardiovascular disease, helicopter pylori bacterial infections and dental diseases (5)(6)(7)(8)(9).
In today's treatment protocols of various comorbid medical conditions over-the-counter drugs and poly-pharmacy are commonly practised. Therefore, when multiple active drugs are ingested for risk prevention strategies there needs to be a vigil for any clinically relevant drug-drug interaction that may occur leading to either manifestation of an overt safety issue or compromising of efficacy resulting in a treatment failure (10)(11)(12). In this context, ingestion of fruit juices such as cranberry juice, especially in patient populations on poly-pharmacy, may introduce a further complication, since cranberry juice contains several active components (13) which may have the potential to interfere in the absorption, metabolism and/or excretion of the interactions, especially the topic of grapefruit juice causing significant clinical herb-drug interactions, via CYP enzymes and transporters (14)(15)(16)(17).

SCOPE
The intent of this review is to collate the in vitro, preclinical and clinical data of published work where potential interaction with cranberry juice has been evaluated and to provide perspectives in light of the evidence gathered on the potential unwanted effects of the use of cranberry juice from the point of view of clinical herb-drug interaction.

METHODS
Using a Medline (Pubmed) search with terms such as cranberry juice, pharmacokinetics, clinical, preclinical or in vitro, relevant articles pertaining to the published work on cranberry juice were screened using drug-drug interaction as a key search tool. Accordingly, data were collated into appropriate sub-headings pertaining to in vitro, preclinical and clinical studies for further data evaluation and interpretation.

IN VITRO/PRECLINICAL
Human liver microsomal CYP3A -midazolam probe substrate Ngo et al (2009) have conducted an impressive investigation to pin-point the fraction of the cranberry juice that was more likely to inhibit human CYP3A4 enzyme (18). In this work, five different cranberry juice brands were tested in a blinded manner, since the active components present in the cranberry juice may vary based on the collection and/or storage of fruits and processing conditions (18). The incubation of midazolam as a probe for CYP3A4 in human liver microsomes was performed with the five cranberry juice brands and a control treatment. The formation of 1-hydroxymidazolam activity was monitored as the surrogate for CYP3A activity. Four of the five brands provided a concentration dependent inhibition of CYP3A activity in the human liver microsomes (18). However, the extent of inhibition at comparable time point varied between the four brands of cranberry juice. At the lowest amount of the juice tested (0.05% v/v) the extent of CYP3A4 inhibition relative to the control was almost 2-fold different between the brand that produced the highest CYP3A4 inhibition (68%) and one that had the least inhibition (34%) (18). In only 2 out of 5 brands of cranberry juice tested at the higher concentrations (0.5%, v/v) was CYP3A4 activity completely inhibited , which was comparable to the complete inhibition produced by ketoconazole (2 µM concentration) used as a positive control in this experiment (18). One brand of cranberry juice that produced maximum CYP3A inhibition was selected for further in vivo characterization. This brand of cranberry juice was subjected to extraction and fractionation into various solvent systems, namely hexane, chloroform, butanol and an aqueous soluble phase. Each of the four fractions was characterized for its ability to inhibit CYP3A4 activity using human liver microsomes and midazolam as the index substrate (18). All four fractions showed CYP3A inhibition in a concentration dependent manner. Interestingly, the CYP3A4 inhibition was strongly correlated with the hydrophobicity of the fraction. The more hydrophobic fraction (n-hexane) showed maximal CYP3A4 inhibition as compared to the least hydrophobic aqueous phase, relative to the control activity (18). Therefore, this crucial fractionation experiment provided a hint that the CYP3A inhibition activity of cranberry juice may be associated with more hydrophobic active constituents of the juice (18). Ngo et al (2009) evaluated the ability of the chosen brand of cranberry juice and the associated 4 fractions described above to inhibit the polymorphic CYP3A5 enzyme relative to CYP3A4 enzyme, using human recombinant enzymes and midazolam as the probe substrate and monitoring the formation of 1'hydroxymidazolam activity. This experiment was performed using both rCYP3A4 and rCYP3A5 systems with positive control, ketoconazole. It was evident that the intact juice and 4 fractions showed concentration-dependent inhibition of both recombinant CYP3A enzymes (18). However, rCYP3A4 inhibition was relatively higher as compared to rCYP3A5 inhibition across the 4 fractions and the intact cranberry juice. For instance, n-hexane fraction (50 µg/ml concentration) inhibited rCYP3A4 and rCYP3A5 by 75% and 62%, respectively. Regardless of the two rCYP3A enzymes tested, the n-hexane fraction showed the maximum inhibition compared to all other fractions (18). Ngo et al (2009) utilized Caco-2 cell monolayers to test the role of cranberry juice on the absorptive permeability of an index substrate, midazolam. The absorption potential of midazolam across the monolayer was tested in different in vitro conditions that encompassed an acidic pH environment mimicking small intestine (pH 5.5), diluted/pH neutralized (pH7.4; 1:4 dilution of the juice) and high glucose concentration at neutral pH (glucose: 50 g/L, pH 7.4) (18). Since only one in vitro condition incorporated cranberry juice, the design could tease out if they were factors outside of cranberry juice, such as acidic conditions and/or high sugar content that would mediate the absorption of midazolam across the human intestine mono layers (18). The evidence suggested that only cranberry juice treatment had a significant effect on the transport of midazolam across the mono layers. The inhibitory effect on the absorption of midazolam was quite apparent after 1 hour of incubation. It was found that the amount of midazolam recovered in the basolateral compartment was at least 34 to 47% lower for the cranberry juice treatment as compared to control and other in vitro conditions tested. This neatly designed cascade of experiments unequivocally confirmed that cranberry juice had the potential to interfere in the permeability/transport of midazolam across the Caco 2-cell monolayers (18).

Inhibition of absorptive permeability of midazolam across the small intestine
Human liver microsomal CYP2C9 -warfarin as the probe substrate Ngo et al (2010) have evaluated the ability of cranberry juice to inhibit the human liver microsome CYP2C9 activity. In this work, five different cranberry juice brands were tested in a blinded manner at three concentration levels (0.05%, 0.2% and 0.5% v/v). Incubation of Swarfarin as a probe for CYP2C9 in human liver microsomal preparations for 30 minutes was performed with the five cranberry juice brands and the control treatment (19). The formation of 7-hydroxywarfarin activity was monitored as the surrogate for CYP2C9 activity. Only one brand of cranberry juice out of 5 tested produced a concentration dependent inhibition of CYP2C9 activity in the human liver microsomes (19). It appeared that at a concentration of 0.2% v/v cranberry juice >50% of CYP2C9 activity was inhibited and at a higher concentration of 0.5% v/v of cranberry juice almost 90-95% of CYP2C9 activity was inhibited (19). The positive control sulfaphenazole inhibited the CYP2C9 activity by over 95%, suggesting that at a higher concentration of 0.5% v/v or above cranberry juice was equally potent as a CYP2C9 inhibitor (19).
Each of the four fractions above was characterized on its ability to inhibit CYP2C9 activity in human liver microsomes using Swarfarin as the index substrate (19). All four fractions displayed CYP2C9 inhibition in a dose or concentration dependent manner. Interestingly, the CYP2C9 inhibition was strongly correlated with the chloroform fraction compared to either a more hydrophobic fraction (n-hexane) or more hydrophilic fraction (19). The chloroform fraction produced an inhibition of 32% and 75% at the tested concentrations of 10 µg/ml and 50 µg/ml, respectively. Therefore, this crucial fractionation experiment provided a hint that the CYP2C9 inhibition activity of cranberry juice may be associated with a different fraction of the juice as compared to CYP3A inhibition (18,19).
Human liver microsomal CYP2C9 -diclofenac as the probe substrate Ushigima et al (2009) evaluated the ability of cranberry juice to inhibit the human liver microsomal CYP2C9 activity using diclofenac as the probe substrate. The well-established potent CYP2C9 inhibitor sulfaphenazole was used as a positive control. Upon incubation with various amounts of cranberry juice, CYP2C9 activity in the human liver microsomes was inhibited in a concentration dependent manner, such that an IC50 value of 1.14% v/v was established for the cranberry juice (20). The relative IC50 value established for sulfaphenazole in the same human liver microsomes was 0.4 µM. This confirmed that cranberry juice at a higher dose was a potent inhibitor of CYP2C9, with complete abolition of the metabolism of diclofenac (20).
Human liver microsomal CYP2C9flurbiprofen as the probe substrate Greenblatt et al (2006) demonstrated the ability of many beverages such as cranberry juice, grape juice and brewed tea to inhibit CYP2C9 mediated hydroxylation of flurbiprofen in a freshly prepared human microsomal system (21). Fluoconazole, a potent CYP2C9 inhibitor, was used as the positive control. Cranberry juice showed a concentration dependent inhibition of liver microsomal CYP2C9 and the IC50 value for the CYP2C9 inhibition was about 2.5% v/v (21). Interestingly, tea beverage showed much more potent CYP2C9 inhibition by a leftward shift in its response curve when superimposed on cranberry juice, with an IC50 value of about 1.2 % for CYP2C9 inhibition (21). Grape juice also behaved in an identical manner to that of tea beverage (flurbiprofen hydroxylation was reduced by 10-11% of control at a concentration of 2.5% v/v). The index inhibitor sulfaphenazole inhibited flurbiprofen hydroxylation pathway by 4-fold as compared to the control treatment (21% ) at 2.5 µmol/L. Fluconazole inhibited the CYP2C9 mediated activity of human liver microsomes with an IC50 value of 29.5 µM (21). Therefore, it appeared that both tea beverage and grape juice had a greater potential of CYP2C9 inhibition than cranberry juice at equivalent concentrations of the three beverages (21).

Rat intestinal microsomes/human liver microsomes -nifedepine as the probe substrate
The work of Ueswa and Mohri (2006) suggested that cranberry juice had the potential to inhibit the CYP3A mediated activity which was involved in the oxidation of nifedepine in both rat intestine microsomes and human liver microsomes (22). The decrease observed with cranberry juice pretreatment, however, was moderate (13-18% inhibition) as compared to grapefruit juice pretreatment (58 -63% inhibition) in rat intestinal and human liver microsomal systems. It appeared that mechanism based inhibition of nifedipine oxidation by cranberry juice was not as potent as that observed with grapefruit juice (22).

Preclinical -Nifedipine
In an interesting study in rats, the pharmacokinetics of nifedipine was investigated with separate pre-treatment of cranberry juice and grapefruit juice in relation to water treatment (22). Each treatment group had 5 animals to support the statistical analysis of any observed pharmacokinetic differences (22). Both cranberry juice and grapefruit juice influenced the rate and extent of nifedipine oral absorption, relative to the control treatment. Although peak levels for nifedipine were numerically greater for both juice treatments (about 20%) relative to water treatment this did not reach statistical significance (22). However, the AUC(0-) values for nifedipine were approximately 1.61 to 1.65 fold higher for both juice treatments as compare to the water comparator arm. With the exception of total body clearance of nifedipine, which was reduced by 40-45% for both juice treatments relative to control, the other parameters such as volume of distribution, mean residence time and elimination half-life were not statistically significantly different from the control treatment values (22). Therefore, it was concluded that both cranberry juice and grapefruit juice reduced the presystemic clearance of nifedipine by inhibiting the intestinal CYP3A metabolism and improved the oral bioavailability of the drug. There was no evidence of inhibition of hepatic CYP3A metabolism of nifedipine by either of the two juices (22).

Study 1
Ngo et al (2009) evaluated the pharmacokinetics of midazolam in presence of a double-strength cranberry juice (double strength juice was prepared by reconstituting cranberry juice in half the amount of recommended water to yield a 200% concentrated juice) that produced the maximum CYP3A4 inhibition in the in vitro characterization of various brands of cranberry juice (18). The water treatment was used as the control arm. The study was a 2-way randomized crossover in 16 healthy volunteers with an adequate washout period between the treatments. Consistent with the in vitro cell permeability experiment, the presence of cranberry juice slowed the absorption rate of midazolam relative to the water treatment (18). Although there was variability, consistent lowering of Cmax of midazolam was observed, such that the geometric mean value for cranberry juice was at least 31% lower than the geometric mean obtained for the water treatment. The delay in time to peak levels of midazolam was evident in all subjects and a large variation of 2 to 8-fold was observed (18). Although midazolam absorption rate was hindered by cranberry juice, the extent of absorption of midazolam was much higher for the cranberry juice treatment relatively to the water treatment. The geometric mean AUC(0-) value for midazolam was 33% higher for the cranberry juice relative to the control treatment (18). Furthermore, this increase in exposure was clearly reflected in the oral clearance of midazolam for cranberry juice, which was approximately 25% lower as compared to the water treatment (18). In spite of the observed changes in absorption rate and total exposure, the elimination half-life values for midazolam appeared to be consistent between the two treatments, suggesting that hepatic CYP system had no influence on the observed changes in midazolam pharmacokinetics with cranberry juice intake (18).
The measurement of the 1'hydroxymidazolam metabolite provided unequivocal confirmation that cranberry juice had an inhibitory effect on the intestinal CYP3A metabolism of midazolam (18). The formation and appearance of 1'-hydroxymidazolam in the systemic circulation was significantly delayed for the cranberry juice treatment and the geometric mean Cmax level for cranberry juice was almost 3fold lower than the water treatment (18). The extent of formation of metabolite measured by AUC(0-) value for 1'-hydroxymidazolam was much lower for the cranberry juice relative to water treatment, confirming that both rate and extent of metabolite formation was affected by cranberry juice due to the intestinal inhibition of CYP3A4 by cranberry juice. As was noted earlier for the parent compound, the elimination half-life for 1'-hydroxymidazolam was unaltered by cranberry juice, suggesting that cranberry juice had no impact on the hepatic enzymatic system (18). Interestingly, the computation of metabolite to parent AUC(0-) ratio for water treatment (0.34) and cranberry juice (0.21) also suggested that indeed bioavailability of midazolam increased, resulting in a greater exposure of the parent and lower formation of metabolite with cranberry juice intake (18).

Study 2
As part of a 3-drug cocktail probe, the pharmacokinetics of midazolam, used as a model substrate to measure the CYP3A4 activity, was studied after continuous pre-treatment with 200 ml of regular cranberry juice (regular cranberry juice was prepared by reconstituting cranberry juice with water in a 1:4 v/v) three times daily for 10 days relative to water control treatment (23). This was a randomized crossover study in 10 healthy volunteers, with two treatments (cranberry juice and water), and a long washout period that lasted for 4 weeks. On the study day (i.e., day 5), the frequency of intake of 200 ml cranberry juice was changed to four times instead of three times. The pre-treatment with cranberry juice had no influence on the pharmacokinetic profile of midazolam as reflected by AUC(0-) values (cranberry juice: 4.32 ng/ml.hr vs water: 4.38 ng/ml.hr), Cmax values (cranberry juice: 1.69 ng/ml and water: 1.49 ng/ml) and comparable elimination half-life values (2.5 -2.7 h) between the two treatments (23). The AUC(0-) ratio of midazolam/10-OH-midazolam closely matched the values between cranberry juice (4.26) and water treatments (4.35). In summary, under the experimental conditions studied cranberry juice (200 ml given three times daily and then four times daily for 10 days) did not inhibit CYP3A4 activity, as evidenced by similar pharmacokinetic data of the parent midazolam and its metabolite (23).

Study 1
The study involved the use of a double strength cranberry juice (a total of 720 ml of cranberry juice was consumed in three-240 ml aliquots, with each 240 ml aliquot of cranberry juice consumed in a 15-min time interval) that had shown the highest in vitro inhibition of CYP2C9 in human liver microsomes as measured by the 7hydroxylation pathway of S-warfarin (19). In total, 16 volunteers participated in this study which was a crossover design of two treatments, double-strength cranberry juice and the water control arm. Cranberry juice had a measurable impact by slowing the absorption rate of both warfarin enantiomers, as reflected in the lowering of peak concentration levels (19). There was a relatively long delay in the time for the appearance of the peak levels in plasma (2-fold and 3-fold for R-warfarin and S-Warfarin, respectively). The geometric mean of Cmax for Swarfarin (1.5 µM) for the cranberry juice treatment was 25% lower than that of the water treatment (2 µM). Similarly, the mean Cmax for Rwarfarin (1.4 µM) for the cranberry juice treatment was >20% lower than water treatment (1.7 µM) (19). Hence, for both warfarin enantiomers the 90% confidence interval for bioequivalence between the cranberry juice and water treatments was outside the 80 -125% window, suggesting that peak concentrations were significantly affected by the cranberry juice (19). In contrast, the AUC(0-)values tended to be similar for the cranberry juice treatment relative to water treatment for both warfarin enantiomers. Hence the comparison of the geometric point estimate with 90% confidence intervals rendered bioequivalence for either of the two warfarin enantiomers between the cranberry juice and water treatments (19). The elimination half-life values appeared to be similar between the two treatments for both R-and S-warfarin. Overall, although it appeared that cranberry juice may have altered the absorption rate of both warfarin enantiomers, it did not significantly alter the extent of absorption of the two warfarin enantiomers, relative to the control treatment (19).

Study 2
As part of a 3-drug cocktail probe the pharmacokinetics of warfarin, an index substrate to measure the CYP2C9 activity, was studied after continuous pre-treatment with 200 ml of regular cranberry juice (regular cranberry juice was prepared by reconstituting cranberry juice with water in a 1:4 v/v) three times daily for 10 days relative to water control treatment (23). This was a randomized crossover study in 10 healthy volunteers, with two treatments (cranberry juice and water) and a long washout period that lasted 4 weeks. On the study day (i.e. day 5), the frequency of intake of 200 ml cranberry juice was changed to four times daily instead of three times. The pre-treatment with cranberry juice showed no alterations in the pharmacokinetic parameters of either warfarin enantiomers (23). The AUC(0-) values (cranberry juice: R-warfarin 26.8 ng/ml.hr; S-warfarin 19.3 ng/ml.hr vs water: R-warfarin 26.4 ng/ml.hr; S-warfarin 20.7 ng/ml.hr)), Cmax values (cranberry juice: R-warfarin 0.49 ng/ml.hr; S-warfarin 0.50 ng/ml vs water: R-warfarin 0.51 ng/ml.hr; S-warfarin 0.52 ng/ml.hr)), and elimination half-life values (cranberry juice: Rwarfarin 44.7 hr; S-warfarin 36.4 hr vs water: Rwarfarin 44.4 hr; S-warfarin 40.3 hr) were found to be similar between the two treatments (23). The pharmacodynamic variables such as thromboplastin timeAUE0-168 (cranberry juice: 3665 s hr vs water: 3624 s hr) and Emax for thromboplastin time (cranberry juice: 24.5 s vs water: 24 s) measured in this study were found to be similar for the two treatments, suggesting that cranberry juice did not impair the anti-coagulation activity of warfarin (23). In summary, under a rigorous daily dosing of cranberry juice, there were no apparent signs of inhibition CYP2C9 activity, as evidenced by similar pharmacokinetic data and pharmacodynamics of warfarin enantiomers between the two treatments (23).

Study 3
Ansell et al (2009) studied the pharmacokineticpharmacodynamic interaction of warfarin with cranberry juice in a blinded manner in 30 patients (14 patients assigned to cranberry juice and 16 patients assigned to water control treatment) (24). The chosen patients for this study were on a stable dose of warfarin to achieve the required therapeutic anti-coagulation level, as determined by the INR. The 30 patients per the randomization schedule either received cranberry juice (approximately 240 ml concentrate containing 27% cranberry juice) or the matching placebo treatment (approximately 240 ml of placebo similar in colour and taste with that of cranberry juice concentrate) once daily for 14 days (24). The plasma concentrations of warfarin enantiomers were determined during the dosing period of 2 weeks and one-week follow up thereafter. Similarly, INR values were noted to measure the effect of cranberry juice on the dynamics of warfarin (Ansell et al, 2009) (24). No statistically significant differences were noted in the plasma concentrations of either S-warfarin or R-warfarin when appropriate comparisons (leadin period or treatment period) were made between the cranberry juice vs placebo treated groups (24). The pharmacokinetic results confirmed the earlier reports that cranberry juice may not inhibit warfarin metabolism mediated via CYP2C9. In terms of pharmacodynamics, the pre-treatment with cranberry juice did not have a significant impact on the measured INR values at various time points during the lead-in, treatment or follow-up period of the investigation, with the exception of a single point on day 12 of treatment. Although numerically INR values appeared to be small, differences were statistically significant compared to placebo treatment (24).

Study 4
Mellen et al (2009) carried out a prospective pharmacodynamic interaction study in patient populations which were stabilized for a therapeutic anti-coagulation effect of warfarin with INRs of 2-3 (25). No change in warfarin dose for a 4 week observation period and a maximum of 10% fluctuation in the repeat INR measurements were key inclusion criteria for patient enrolment in this prospective study (25). There were ten patients that enrolled in this study. The cranberry juice was ingested every day (240 ml juice on a twice daily schedule) for 7 days by all patients. The patients continued on their daily dose of warfarin during the entire study. Both INRs and prothrombin times were measured at day 0 prior to cranberry juice intake and on days 2, 6 and 8 of the study (25). The results confirmed that cranberry juice had no apparent effect on prothrombin times on days 2, 6 and 8 when compared to the baseline value collected on day 0 (it appeared to be within the defined boundary of 12.9 to 15). In addition, the pre-treatment with double strength juice had no impact on INRs, which remained stable between 2 and 3 during the entire study protocol (25). The data from one patient was excluded since the patient developed diarrhoea soon after study initiation and this patient did not consume any more cranberry juice and his warfarin dose was withheld until the diarrhoea resolved (25). Abdul et al (2008) reported a pharmacodynamic interaction between cranberry juice and a single high dose of warfarin in healthy subjects (26). In a three-way randomized crossover design, 12 healthy male subjects received one of three treatments: a) single dose of warfarin after 2-week pre-treatment with cranberry juice concentrate capsules (1000 mg cranberry juice concentrate, three times daily) followed by another week of cranberry juice concentrate capsules; b) single dose of warfarin 2-week pre-treatment with garlic and c) single dose of warfarin with water (26). The PKPD assessments were done by quantifying the plasma concentrations of R-and S-warfarin and the measurement of individual subject INR. Cranberry juice concentrate or garlic did not alter the pharmacokinetics of either of the two enantiomers relative to the control treatment and produced identical exposure and elimination halflife values (26). However, cranberry juice concentrate but not garlic showed statistically significant difference in the INR value -almost 30% increases in the area under the INR time curve-suggesting that there was a potential susceptibility for a pharmacodynamic interaction in the patient population (26). Another important finding of this study was that both cranberry juice concentrate and garlic provided hints of VKORC1 (not CYP2C9) genotype-dependent interactions with warfarin, which may have bearing in the patient population (26).

Study 6
Li et al (2006) performed a blinded 2-way crossover study that involved comparison of pretreatment of cranberry juice vs water for 7 days in 7 patients with atrial fibrillation on a stable dose of warfarin for at least 3 months (27 (27). It was concluded that avoidance of cranberry juice was not necessary for patients on warfarin; however, a close vigil on INR was recommended (27).

Diclofenac
The clinical study was performed as a 2-way randomized crossover with cranberry juice (180 ml of 27% cranberry juice concentrate, twice daily for 5 days) and water (180 ml of water, twice daily for 5 days) treatments with at least a week wash-out period (20). The study involved 8 subjects who had similar CYP2C9 genotype status (*1/*1) to ensure that the outcome was not influenced by the genetic composition of the subjects (20). Following a single oral dose of diclofenac, there appeared to be no alteration in either the rate or extent of absorption of diclofenac in cranberry juice treatment relative to the water control. A similar trend was observed in the absorption and disposition of diclofenac upon multiple daily doses of cranberry juice, suggesting that the in vitro observations of CYP2C9 inhibition could not be replicated in the clinic (20). Since the protein bound and unbound fraction of diclofenac was measured in this study for both in vivo plasma samples and in the in vitro liver microsomes, there was a hint that the protein binding of diclofenac may have played a role to explain the discrepancy between the in vitro and in vivo findings. Because a major part of diclofenac existed in the unbound form in vitro it enabled a constant delivery of the substrate to fuel the enzymatic activity; however, in vivo the high protein binding of diclofenac may have limited the supply of the substrate to the metabolising enzyme (20).

Amoxicillin
Li et al (2009) investigated the pharmacokinetics of amoxicillin after a chronic dosing with cranberry juice (chronic dosing of cranberry juice comprised of administration of approximately 360 ml of cranberry juice, twice daily, for two days) relative to a water control treatment (28). The study was conducted in eighteen healthy female subjects with four treatments administered in a fixed-sequence crossover manner with a 7-day washout period. Two doses of amoxicillin (500 mg and 2 g) were used with and without 180 ml of co-administered cranberry juice at the time of dosing (28) With the exception of a shift in time to peak levels of amoxicillin (approximately 1 hr), cranberry juice did not have any other impact on the pharmacokinetic disposition of amoxicillin at both doses tested relative to water control treatment. For example at the 500 mg dose, the AUC (cranberry juice: 23.7 µg/ml.hr vs water: 24.9 µg/ml.hr), oral clearance ((cranberry juice: 367 ml/min vs water: 347 ml/min), elimination half-life ((cranberry juice: 1.05 h vs water: 1.13 h) and renal clearance (cranberry juice: 236 ml/min vs water: 218 ml/min) were almost identical for both treatments (28). Similarly, cranberry juice had negligible influence on the derived pharmacokinetic parameters at the 2 g dose of amoxicillin. The results with amoxicillin appeared to suggest that cranberry juice had a limited role in the inhibition of efflux transporters that would impede oral drug transport/permeability of certain categories of drugs (28).

Ceflacor
Li et al (2009) have reported the clinical pharmacokinetics of ceflacor after a chronic dosing with cranberry juice (chronic dosing of cranberry juice comprised of administration of approximately 360 ml of cranberry juice, twice daily, for two days) relative to a water control treatment (28). The study was conducted in eighteen healthy female subjects in a randomised crossover fashion with a 7-day washout period between the two treatments. A single dose of 500 mg ceflacor was administered in this study with and without 180 ml of co-administered cranberry juice at the time of dosing. Cranberry juice did not have any influence on the pharmacokinetic parameters of ceflacor relative to water control treatment (28). For example, the AUC (cranberry juice: 20.5 µg/ml.hr vs water: 21.2 µg/ml.hr), oral clearance ((cranberry juice: 408 ml/min vs water: 397 ml/min), elimination half-life ((cranberry juice: 0.62 hr vs water: 0.59 hr) and renal clearance (cranberry juice: 310 ml/min vs water: 307 ml/min) were almost overlapping between the two treatments (28).

Tizanidine
As part of a 3-drug cocktail probe the pharmacokinetics of tizanidine, a model substrate to measure the CYP1A2 activity, was studied after continuous pre-treatment with regular cranberry juice three times daily for 10 days relative to water control treatment (23). This was a randomized crossover study in 10 healthy volunteers, with two treatments (cranberry juice and water) and a long washout period that lasted 4 weeks (23). On the study day (i.e. day 5), the frequency of intake of 200 ml cranberry juice was changed to four times instead of three times. The pharmacokinetic disposition of tizadine was unaltered by the pre-treatment of cranberry juice as gauged by AUC(0-) values (cranberry juice: 2.16 ng/ml.hr vs water: 2.58 ng/ml.hr) and almost similar elimination half-life values (1.2 -1.3 hr) between the two treatments. Two metabolites of tizadine (M-3 and M-4) were also quantitated and the AUC(0-) ratio of tizadine/M-3 was identical between cranberry juice (5.13) and water treatments (4.86) (23). Similarly, AUC(0-) ratio tiazidine/M-4 was comparable between cranberry juice (5.89) and water treatments (6.43). In summary, cranberry juice did not inhibit CYP1A2 activity, as evidenced by the unaltered data of the parent tizanidine and its two major metabolites, M-3 and M-4 (23).

Flurbiprofen
The investigation reported by Greenblatt et al (2006) evaluated the effect of pre-treatment of several beverages such as cranberry juice, grape juice and tea on the pharmacokinetics of flurbiprofen relative to water control treatment (21). This was a randomized design in fourteen healthy volunteers that had five treatment arms, namely: water/placebo, cranberry juice, tea beverage, grape juice and fluconazole, with one week washout period (21). The beverage treatment was applied the night before and 30 minutes (on each of the two occasions, approximately 240 ml of the respective beverage was consumed) before flurbiprofen administration on the study day. The pharmacokinetics of flurbiprofen was unaffected by the pre-treatment with cranberry juice, as indicated by the extent of absorption, AUC(0-) (cranberry juice: 62 ug/ml.hr vs placebo: 59 ug/ml.hr), oral clearance (cranberry juice: 29.3 ml/min vs placebo: 30.5 ml/min) and elimination half-life values (cranberry juice: 3.4 h vs placebo: 3.3 h) (21). Also, Cranberry juice produced identical exposure of 4-hydroxyflurbiprofen (1.16 ug/ml.hr) as compared to placebo treatment (1.24 ug/ml.hr) (21). In sharp contrast, fluconazole pretreatment, increased the exposure of flurbiprofen by almost 2-fold relative to placebo and decreased the oral clearance of flurbiprofen by an identical 2-fold margin as compared to placebo. The potent CYP2C9 inhibition of flurbiprofen also resulted in an almost 55% reduced exposure of 4-hydroxyflurbiprofen relative to placebo treatment (21). The other beverages (grape juice and brewed tea) failed to interfere with the pharmacokinetics and metabolism of flurbiprofen under in vivo conditions, contrary to the in vitro CYP2C9 inhibition data (21).

Cyclosporine
The work of Grenier et al (2006) evaluated the influence of the co-administered fruit juices such as cranberry juice (240 ml) and pomelo juice (240 ml) on the pharmacokinetics of cyclosporine relative to 240 ml water treatment (29). This was a 3-way randomized crossover design, with three sequences and 3 treatments with a 2-week washout period involving 12 healthy human volunteers. Pomelo juice but not cranberry juice showed significant impact on the pharmacokinetics of orally administered cyclosporine (29). Both absorption rate and extent of absorption of cyclosporine were higher following pre-treatment with pomelo juice (Cmax values: pomelo juice: 1494 ng/ml vs cranberry juice: 1262 vs water: 1327 ng/ml and AUC(0-) values: pomelo juice: 6835 ng/ml.hr vs cranberry juice: 5217 ng/ml.hr vs water: 5753 ng/ml.hr) relative to other two treatments (29). However, the elimination half-life of cyclosporine (10-11 hr) was comparable across all treatments, suggesting that the effect of pomelo juice was only on the intestinal metabolism/transport of cyclosporine (29).

Salicylate
The work of Duthie et al (2005) confirmed the positive effect of cranberry juice intake on the intestinal absorption of endogenous salicylic acid. The study consisted of parallel treatments of cranberry juice (250 mL three time daily) and placebo (250 mL water three times daily) for 2weeks in two cohorts of healthy female subjects (n=11 per group) who were matched for demographics such as height, weight and age (30). Assays were set up to quantify the levels of salicylates (salicylic acid and salicyluric acid) in urine and salicylic acid in plasma. The cohort that had daily intake of cranberry juice produced higher levels of salicylates in the urine within the first week of treatment and by the second week of treatment the plasma salicylic acid concentrations were higher than the placebo group (30). The study confirmed that regular intake of cranberry juice would significantly improve the absorption of endogenous salicylates for potential therapeutic anti-inflammatory benefit (30).

General
The evidence presented in this review, assimilating the extensive research on cranberry juice for over a decade, has suggested that cranberry juice has the potential to inhibit enzymes (CYP3A and CYP2C9) and transporter (Pgp) under in vitro conditions ( Table 1). The in vitro potency of CYP3A inhibition for cranberry juice appeared to be similar or superior to grapefruit juice and pomegranate juice [ Figure 1]; however, cranberry juice may not be as potent as grapefruit juice, tea beverage or pomegranate juice in its in vitro inhibition of CYP2C9 [ Figure  2]. Nevertheless, the IC50 values attained in these studies suggested that a 240 ml volume of regular cranberry juice or double-strength cranberry juice would contain reasonable amounts of the active principles to translate the observed in vitro findings into a clinically relevant interaction in humans. However, in all the clinical case studies gathered in this review from a pharmacokinetic perspective, with the exception of a single report of a mild-moderate CYP3A4 inhibition of the probe substrate midazolam, none of the substrates whose oxidative metabolism was dependent on several CYP enzymes (CYP34, CYP2C9 or CYP1A2) or transporters (Pgp) showed clinically relevant pharmacokinetic interaction upon pretreatment with cranberry juice ( Table 1).

Bioavailability of anthocyanins from cranberry juice
The minimal in vivo translatability of the observed in vitro CYP inhibition leads to the key question of whether or not the active principles from cranberry juice responsible for drug interactions are absorbed from the gut into the systemic circulation. No or limited absorption of relevant cranberry juice components would translate into the lack of in vivo effects on the pharmacokinetics of the probe substrates. The interesting work of Milbury et al (2010) performed in 15 healthy subjects suggested that several anthocyanins were bioavailable following the acute ingestion of cranberry juice (31). Out of 15 active anthocyanins present in cranberry juice, at least 7 anthocyanins were measurable in plasma for up to 4 hours post the acute ingestion of cranberry juice. Despite high inter-subject variability, exposure and pharmacokinetics were defined for several active principles in this study (31). The highest circulating species was peonidin 3-galactoside (AUC: 18.7 nmol.h/L) and the remaining circulatory species were in the following rank order: cyanidin 3-arabionside, cyanidin 3-galactoside, peonidin 3-arabinoside, peonidin 3-glucoside, cyanidin 3-glucoside and malvadin 3-glucoside with AUC values of 13.5, 6.89, 5.35, 3.72, 3.66 and 2.55 nmol.h/L, respectively (31). The urinary recoveries of the active principles were very low and ranged from 0.007% to 0.03% of the administered dose. Because the study objective was to explore if anthocyanin concentrations levels reach a threshold required to elicit in vivo quenching of reactive oxygen species, it was concluded that concentrations attained in plasma were low and possibly insufficient to have a direct role (31). However, it was speculated that the plasma levels may potentially induce signal transduction and gene expression pathways. An extrapolation of the observations from this study to the context of lack of in vivo CYP inhibition by cranberry juice would lead to the speculation that concentrations of the active principles were potentially too low for a clinically relevant drug-drug interaction (31).

CYP3A4 inhibition -human relevancy
The in vitro inhibition of CYP3A and as well mechanism based CYP3A inhibition, similar to grapefruit juice, would put cranberry juice in the same league of grapefruit juice for potential CYP3A mediated drug interactions. Furthermore, the unequivocal in vivo inhibition of nifedipine metabolism in rats and overwhelming increase in bioavailability of nifedipine, almost comparable to that of grapefruit juice, suggested that perhaps it may be a strong CYP3A4 inhibitor in humans (22). However, the two clinical studies performed using midazolam as the substrate had disparate findings (18,23). While one study showed no change in the bioavailability of midazolam (23), the other study showed a modest increase in the bioavailability of midazolam (18).
Although it is difficult to pin-point the cause for the discrepancy between the two studies, it is possible that the in vivo absorption of anthocyanins from the cranberry juice administration may have differed widely between the two studies, since one study presented a large single acute intake of cranberry juice whilst the other studyhad a chronic intake of cranberry juice (intake of 3 volumes of 240 mL double strength cranberry juice vs three times daily intake of 200 mL cranberry juice for 5 days) (18,23). To underscore this view, a recent study on the oral bioavailability of active principles of cranberry juice suggested high variability and low systemic bioavailability of only 7 of the active anthocyanins (31). Therefore, it is conceivable that a daily intake or perhaps even a twice daily intake of cranberry juice may not produce enough circulatory anthocyanins to show inhibition of human CYP3A4, which was evident from another clinical study of a second CYP3A4 substrate, cyclosporine, which showed no change in the bioavailability and pharmacokinetics of cyclosporine from cranberry juice pre-treated subjects (29). In sharp contrast and to put things into perspective, pre-treatment of grapefruit juice consistently increased the bioavailability of both midazolam (AUC change: 52% to 106%) (32,33) and cyclosporine (AUC change: 45% to 60%; [34][35][36]) in human subjects. These data suggested that cranberry juice, unlike grapefruit juice, would not cause a clinically relevant drug-drug interaction at the dose concentrations studied.   (37).

CYP2C9 inhibition -Human relevancy Pharmacokinetics
The in vitro evidence of cranberry juice as a potent CYP2C9 inhibitor was demonstrated for several substrates such as flurbiprofen, diclofenac and warfarin [ Table 1]. At higher amounts, cranberry juice was as potent as fluconazole, which is a strong CYP2C9 inhibitor under in vitro and in vivo conditions. However, review of all the clinical data involving cranberry juice provided no evidence of altered bioavailability or pharmacokinetics of several substrates such as warfarin, diclofenac and fluribprofen whose metabolism was mediated by CYP2C9 (19)(20)(21)23). Therefore, lack of in vivo inhibitory effects of cranberry juice suggested that under in vivo conditions either the active anthocyanin principles were not reaching adequate levels to produce any CYP2C9 inhibition or the intake amount of cranberry juice itself was insufficient. Since the cranberry juice intake differed (regular vs doublestrength; whole juice vs diluted concentrate etc), as well as the sourcing of the juice itself in the described studies, it may be difficult to pin-point an exact reason for the lack of in vivo inhibition. A number of speculative reasons could be put forward to explain the discrepancy: a) under in vitro conditions all 15 anthocyanin principles may be available to have a concerted effort in CYP2C9 inhibition; however, only 6 or 7 anthocyanin principles were bioavailable and at varying low levels in an in vivo study; b) a faster clearance of the active anthocyanin principles under in vivo conditions may have led to levels not reaching the threshold level to show CYP2C9 inhibition; c) influence of protein binding and/or rapid tissue uptake of the substrate would have been relevant under in vivo conditions, thereby preventing the drug availability to the enzymes. Overall, the clinical data clearly suggested that with daily or chronic intake of normal amounts of cranberry juice there is minimal or negligible potential to show a clinical relevant drug-drug interaction via CYP2C9 pathways.

Pharmacodynamics
The pharmacodynamics aspects of drug-drug interaction potential of cranberry juice in patients prescribed warfarin have received considerable attention. As evident in Table 2, there was one instance of elevated INR in healthy subjects after a single high dose of warfarin following ingestion of a cranberry juice concentrate supplement (26) and an isolated incidence of an increased INR at one particular time point following ingestion of juice during a 2-week treatment period in patients who were stabilized on warfarin (24 (2010) have critically reviewed a number of prospective clinical studies and case reports pertaining to cranberry juice -warfarin interaction and concluded that the warning label of interaction potential between warfarin and cranberry juice needs to be re-visited by the regulators (43).

CONCLUSIONS
Cranberry juice has been long recognized for its protective effects in urinary tract infections. As evidenced by scores of published literature ingestion of cranberry juice may provide therapeutic benefits for other ailments. Given the risk involved in food-drug interaction, as exemplified by grapefruit juice, it is always prudent to understand the probable mechanism(s)  (27) Patients (n=7) INRs remained stable as compared to baseline values during the entire trail CJ: cranberry juice for herb-drug interaction and examine the evidence to obtain guidance for the use of cranberry juice as a herbal supplement for dietary or nutritional needs.Cranberry juice has the potential to inhibit CYP enzymes (CYP3A and CYP2C9) under in vitro conditions, and at higher tested amounts of the juice the extent of inhibition was almost similar to the potent inhibitors of CYP3A (ketoconazole) and CYP2C9 (fluconazole). However, in relation to other beverages such as grape juice, tea and pomegranate juice, it appeared that cranberry juice was less potent in its CYP2C9 inhibitory properties, but the CYP3A inhibition was in line with or superior to grapefruit juice or pomegranate juice. In spite of the in vitro CYP inhibitions or Pgp inhibition produced by cranberry juice, there was no clinical translatability of the evidence in the pharmacokinetic disposition of scores of substrates (cyclosporine, warfarin, diclofenac, flurbiprofen, tizanidine, amoxicillin, ceflacor) with the exception of a single report on midazolam, where there was a moderate increase in the exposure of midazolam in subjects pretreated with cranberry juice. Interestingly, another study concluded lack of clinically relevant in vivo interaction between cranberry juice and midazolam. In general, the lack of in vivo translation of the in vitro CYP inhibition by cranberry juice was evident with the following speculative remarks: a) under in vitro conditions all anthocyanin principles may be available to have a concerted effort in CYP inhibition; however, limited anthocyanin principles at low levels were bioavailable in the in vivo studies; b) a faster clearance of the active anthocyanin principles under in vivo conditions may have led to levels not reaching the threshold level to show CYP inhibition; c) influence of protein binding and/or rapid tissue uptake of the substrate may be relevant under in vivo conditions, thereby limiting the drug availability to the enzymes.
It is noteworthy to provide some conclusive remarks with respect to pharmacodynamics of warfarin after ingestion of cranberry juice. While the debate continues on the issue of a pharmacodynamic interaction between warfarin and cranberry juice, the summation of the pharmacodynamics data obtained in patients and healthy subjects from the various prospective and controlled clinical trials do not provide overwhelming support for a pharmacodynamic drug interaction with cranberry juice. However, it was apparent that consumption of large quantity of cranberry juice (about 1-2 L per day) or concentrate (1000 mg) for a longer duration of time (>3-4 weeks) may be temporally correlated with altered INR values. Therefore, while the total avoidance of cranberry juice by warfarin users may not be warranted by the published studies, in certain situations of higher intake of cranberry juice or concentrate there may be a need to monitor both warfarin doses and INR levels.


extfieldsofstudy: Medicine Biology

text:
IGHV1-69-Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia React with Malondialdehyde–Acetaldehyde Adduct, an Immunodominant Oxidation-Specific Epitope

The immunoglobulins expressed by chronic lymphocytic leukemia (CLL) B cells are highly restricted, suggesting they are selected for binding either self or foreign antigen. Of the immunoglobulin heavy-chain variable (IGHV) genes expressed in CLL, IGHV1-69 is the most common, and often is expressed with little or no somatic mutation, and restricted IGHD and IGHJ gene usage. We found that antibodies encoded by one particular IGHV1-69 subset, designated CLL69C, with the HCDR3 encoded by the IGHD3-3 gene in reading frame 2 and IGHJ6, specifically bound to oxidation-specific epitopes (OSE), which are products of enhanced lipid peroxidation and a major target of innate natural antibodies. Specifically, CLL69C bound immunodominant OSE adducts termed MAA (malondialdehyde–acetaldehyde-adducts), which are found on apoptotic cells, inflammatory tissues, and atherosclerotic lesions. It also reacted specifically with MAA-specific peptide mimotopes. Light chain shuffling indicated that non-stochastically paired L chain of IGLV3-9 contributes to the antigen binding of CLL69C. A nearly identical CLL69C Ig heavy chain was identified from an MAA-enriched umbilical cord phage displayed Fab library, and a derived Fab with the same HCDR3 rearrangement displayed identical MAA-binding properties. These data support the concept that OSE (MAA-epitopes), which are ubiquitous products of inflammation, may play a role in clonal selection and expansion of CLL B cells.

Introduction
Chronic lymphocytic leukemia (CLL) is a malignancy of monoclonal CD5 + B cells, which accumulate in the blood, marrow, and lymphoid tissues [1]. Previous studies found the immunoglobulin (Ig) repertoire expressed in this disease is highly restricted [2,3,4,5,6]. In general, CLL patients that express unmutated Ig heavy chain (IGHV) genes have a worse prognosis than those who express mutated IGHV genes [3,7]. One particular IGHV gene, IGHV1-69, generally is expressed with little or no somatic mutation and is used by CLL cells of approximately 15% of all patients [3,8,9]. Moreover, the IGHV1-69-encoded Ig heavy chains (IgH) expressed in CLL commonly have stereotypic motifs in the third complementarity determining region (HCDR3), resulting from the rearrangement and restricted reading-frame-use of certain IGHD and IGHJ gene segments [4,10,11]. In prior studies, we identified four subsets of IGHV1-69-encoded IgH, expressed in CLL that each were preferentially paired with certain IgL, depending upon their respective HCDR3, [12] designated CLL69-A, -B, -C, and -D (also known as subsets 6, 3, 7H and 3, respectively) [9]. CLL69-A IgH encoded by IGHV1-69/IGHD3-16/IGHJ3 were coexpressed with light chains encoded by IGKV3-20 in all cases and CLL69C heavy chains encoded by IGHV1-69/IGHD3-3/ IGHJ6 were paired with IgL encoded by IGLV3-9 in 77% of cases [12]. The prevalent use of unmutated IGHV1-69 and nonstochastic pairing with light chains suggests that self-and/or common-environmental antigen(s) plays a role in the development and/or progression of CLL [12,13].
Chronic inflammatory diseases, including atherosclerosis, are characterized by an enhanced oxidative state and the accumulation of oxidized low-density lipoproteins (OxLDL), apoptotic cells and apoptotic cellular debris, which also bear many oxidatively-modified lipids and proteins. We have termed such oxidation-related neo-antigens as ''oxidation-specific-epitopes'' (OSE), and shown that OSE are not only greatly enriched in atherosclerotic tissue, but in inflammatory or infectious-disease states [14]. Remarkably, OSE are a major target of innate immunity in general and specifically are the target of , 20-30% of all IgM natural antibodies (NAbs) in mice and in human newborn cord blood [15].
Among the most common end-products of lipid peroxidation is the generation of malondialdehyde (MDA), which is highly reactive and in turn can form simple and complex adducts with proteins. We have shown that such MDA adducts are highly immunogenic and prevalent targets of NAbs in both mice and humans [15]. Among these, there are particularly proinflammatory and immunodominant MDA type adducts with lysines of proteins, termed MAA (malondialdehyde-acetaldehyde adducts), of which the 4-methyl-1,4-dihydropyridine-3,5-dicarbonyl type adduct is a major product [16,17,18]. It has been reported that MAA adducts represent the main antigens produced when proteins are modified with concentrations of MDA exceeding 5 mmol/mL [17,18]. We have recently shown that MAA epitopes are immunodominant targets of IgM NAbs in mice and human newborn plasma [15]. In turn, these NAbs immunostain MAA epitopes on apoptotic cells, as well as in atherosclerotic or other inflammatory tissues [15,18].
Because oxidative processes are ubiquitous, we hypothesized that these OSE might serve as a self-antigen(s) that could stimulate B cells bearing appropriate Ig receptors, thereby enhancing their survival and increasing their risk for incurring transforming events [19]. We identify here that MAA-epitopes strongly reacted with the recombinant antibody (rAb) of the CLL69C subset.

Antigen Preparation and Modifications
The study was reviewed and approved by the Human Research Committee of the University of California San Diego that conforms to the Declaration of Helsinki, and blood and/or tissue samples were collected with written informed consent from the donors (UCSD Human Research Protection Program #071402). For the studies described in this proposal, blood and/or tissue samples from human subjects .18 years of age who sign a consent form prior to undergoing a catherization and angioplasty for therapeutic correction of blockage of the blood vessel. Subjects recruited at UCSD will provide blood samples (,50 ml of blood) and/or any tissue that is retrieved during the procedure deposited on a distal protection device used distal to the site of repair to prevent dislodged tissue from blocking the artery distal to the site of operation by the cardiologist. Subjects who agree to donate a blood sample or tissue during the therapeutic procedure will be asked to sign an IRB approved informed consent form giving permission for the studies as noted above. Less than 50 ml of blood will be collected. Subjects who agree to donate blood/tissue will be asked to sign an IRB approved consent form giving permission for blood/tissue collection. Human LDL was freshly isolated from plasma of healthy donors after an overnight fast by sequential ultra-centrifugation, and modified with MAA, MDA or CuSO4 to generate MAA-LDL, MDA-LDL or copper-oxidized LDL (Cu-OxLDL) respectively, as previously described [15]. Phosphocholine-BSA (PC-BSA) was from Biosearch Technologies.

Peptide Mimotopes
We recently reported in detail the generation of small molecule peptide mimotopes of MAA [20]. In brief: To generate peptide mimotopes of MAA-epitopes present on MDA-LDL, peptide libraries purchased from New England Biolabs (NEB) (Beverly, MA, USA) were screened by biopanning for phages reactive with LRO4 [20]. LRO4 is a natural Ab that was cloned in our laboratory from cholesterol-fed Ldlr 2/2 mice and shown to bind MAA-modified BSA or MAA-LDL. Peptide mimotopes of MAA were synthesized by Peptide 2.0 Inc. (Chantilly, VA, USA). The purity of the all peptides was between 89-95% as assessed by high performance liquid chromatography and mass spectral analysis.

Recombinant CLL69 Ab Production
The recombinant CLL69 Ab was produced in exponentially growing 293T human embryonic kidney cells that were cotransfected with equimolar amounts of IgH and IgL plasmid DNA expression vectors by calcium-phosphate precipitation as described [21,22]. Purified recombinant IgG concentrations were determined by ELISA using human IgG1 as a standard.
Chemiluminescent ELISA for Binding to OSE and Mimotopes by CLL69 rAb and Fab Antibody (Ab) binding assays were performed using chemiluminescent technology as described [23] with modifications. Round-bottomed MicroFluor 96-well plates (DYNEX Technologies, Chantilly, VA) were coated with various antigens at 5 mg/mL (50 ml per well) in PBS overnight at 4uC. Synthetic peptides were directly coated at 10 mg/mL (P1) or 5 mg/mL (P2) in 0.1 M NaHCO 3 buffer (pH 8.6), unless indicated differently. Biotinylated peptides were immobilized at indicated concentrations in 0.1 M NaHCO 3 buffer (pH 8.6) on wells pre-coated with 10 mg/mL neutravidin (Pierce, Rockford, IL, USA). After the plates were washed and blocked with 1% BSA in PBS for 30 min, 25 mL of primary Abs diluted with 1% BSA-PBS were added to the wells, and incubated for 90 min at room temperature. Bound Abs were detected with isotype-specific goat anti-human IgG1 alkaline phosphatase conjugate (Southern Biotech), or alkaline phosphatase conjugated anti-HA mAb (SIGMA) for Fab, in Tris buffered saline (TBS) buffer containing 1% BSA, followed by a rinse with water and the addition of 25 mL of 50% LumiPhos 530 (Lumigen, Southfield, MI) as luminescent substrate. The quantitative readout of these assays is light emission, measured as relative light units (RLU) over 100 ms (RLU/100ms) using a Dynex Luminometer (DYNEX Technologies). All determinations were done in triplicate. The specificity of rAb binding was determined by competition chemiluminescent ELISA as described previously [23], and data expressed as B/B 0 , where B represents binding in the presence and B 0 in the absence of competitor.

CLL69 Homologous Gene Isolation and Sequence Analysis
An umbilical cord (UC) Fab phage display library was constructed as described by Barbas et al. [24] and will be reported on in detail elsewhere. For studies described here, the phage libraries were screened for binding to MAA-BSA and MDA-LDL, using the chemiluminescence immunoassay. Target distinct IGHV1-69 genes were amplified from the selected UC phage library using a CDR2-specific sense primer corresponding to the sequence encoding amino acid positions 50-58 of the IGHV1-69 allelic subsets (59-AGGGATCATCCCTATCTTTGGTAC-39) and an antisense primer for germline IGHJ6 consensus sequence (59-GRGGAGACGGTGACCAGGGT-39). The HCDR3 and flanking regions of IGHV1-69 genes were amplified using 5 ml of phage DNA template (10e10 phage) from each phage library panned for 4 th -round of MAA-BSA. PCR products were analyzed on 2% agarose gel and subcloned into a TA cloning vector pCR2.1 (Invitrogen) for sequence determination. To isolate an IGHV1-69 homologous Fab clone, the UC Fab phage display library was also screened with a murine anti-idiotypic mAb G6 [25], which reacts only with IgH encoded by unmutated IGHV1-69 genes [10]. The reactive phage particles were selected by panning on ELISA plates coated with mAb G6 at 1 mg/well. After three rounds of panning, the phage vector was converted to the plasmid producing soluble Fab. Nucleotide and amino acid sequences of the IGHV from all clones were compared to those contained in public databases by using Ig-BLAST and IMGT/V-QUEST.

Expression and Purification of Soluble Fab Ab
Plasmids were purified from selected Fab phage clones and transformed into E. coli BL21 (DE3) for production of soluble Fab. Purification of His 6 -and HA-tagged Fab Abs was carried using Ni-NTA Agarose (Qiagen) and anti-HA Agarose (Sigma) according to the manufacture's protocols. Briefly, Fab Ab expression was induced with 1 mM isopropyl-D-thiogalactopyranoside in E. coli BL21 (DE3) that had been grown to mid-log phase in SuperBroth media. Following induction, bacteria were grown for 16-20 h at 30uC, harvested and resuspended in lysis buffer (1% of culture volume; 500 mM NaCl, 50 mM NaPi buffer pH 7.5, 0.05% Tween-20, 10 mM imidazole) containing protease inhibitors and lysozyme (200 mg/mL) for 20 min on ice and sonicated for 6610s. The lysate was clarified by centrifugation (20,0006g, 30 min, 4uC), and the supernatant was applied to Ni 2+ -NTA agarose beads (Qiagen), from which His6-tagged Fab constructs were eluted using lysis buffer supplemented with 250 mM imidazole. Fractions containing Fab constructs were pooled and dialyzed against PBS on concentrator column and next purified by application to anti-HA filtration chromatography in TBS buffer. After wash with PBS, the Fab Ab were eluted with 0.1 M glycine (pH 3.0). Elutes were neutralized by 2 M Tris-HCl, pH 9.0 in collected tubes. Purified Fab constructs were concentrated in PBS buffer.
Flow Cytometry and Immunofluorescence Microscopy Analysis of Binding to Apoptotic Cells CLL69 Abs and umbilical Fabs were analyzed for binding to apoptotic cells by flow cytometry analysis as described [15]. Thymocytes harvested from C57BL/6 mice were cultured in cell culture medium and induced to undergo apoptosis by 10 ng/ml PMA (Sigma-Aldrich) for 16 hours as described previously [26]. Apoptosis of Jurkat cells were prepared by exposure to UV irradiation at 20 mJ/cm 2 , and further cultured for 16 hours before use. CLL69 Abs or control Ab (1 mg/ml) diluted in 1% BSA-PBS were incubated with apoptotic thymocytes or Jurkat cells for 1 hr at 4uC, followed by incubation with FITC-labeled goat antihuman IgG1 (Southern Biotech) or FITC-labeled anti-HA mAb in 1% BSA-PBS for 30 minutes at 4uC. Apoptotic cells were doublestained with Annexin V -Phycoerythrin (Annexin V -PE) and 7amino-actinomycin (7-AAD) (BD Biosciences) for 15 minutes and immediately analyzed by flow cytometry using a FACSCanto (BD Biosciences).
For immunofluorescence microscopy studies, the cells were incubated with CLL69 Abs, Fab or secondary Ab controls (as above) containing 1 mg/mL of Hoechst dye (Sigma-Aldrich). The cells were fixed with 3.7% paraformaldehyde for 20 minutes, washed, and re-suspended in PBS with 1%BSA. The cells were spun down on glass slides using cytospin (Thermo Shandon). Images were captured using a DeltaVision deconvolution microscopic system operated by SoftWorx software (Applied Precision) as described previously [15].

Macrophage Binding Assay
Binding of biotinylated MAA-LDL to J774 macrophages plated in microtiter wells was assessed by a chemiluminescent binding assay as described previously [23]. Biotinylated MAA-LDL (5 mg/ ml) was incubated in the absence or presence of CLL69 Ab or Fab at various dilutions overnight at 4uC. The supernatants were then added to macrophages and the binding of biotinylated MAA-LDL detected by AP-labeled NeutrAvidin and chemiluminescent ELISA.

Immunohistochemistry
Immunostaining of formal sucrose-fixed, paraffin-embedded sections of aortas of atherosclerotic Watanabe heritable hyperlipidemic (WHHL) rabbits and human carotid atherosclerotic endarterectomy lesions was performed as described previously [27]. Sections of human or rabbit lesions were blocked with PBS containing 5% horse serum and 2% Fc blocker and stained with diluted CLL69 rAbs (1:200), followed by addition of a biotinylated goat anti-human IgG1 (Southern Biotech) or anti-HA biotin mAb conjugate to detect the bound CLL69 Ab or Fab in the lesions. A Vectastain ABC-alkaline phosphatase kit and a Vector Red alkaline phosphatase chromogenic substrate (Vector Labs, Burlingame, CA, USA) were used to visualize Ab staining. Sections were counterstained with Weigert's Iron Hematoxylin (Richard-Allan Scientific, Kalamazoo, MI, USA). Immunostaining of adjacent sections in the absence of primary Abs or VH3-21 rAb were used as negative controls. Endogenous tissue AP activity was blocked by 15 minutes of incubation with 5 mM levamisole (Sigma Chemical Co.).

Oxidation-specific Epitopes are Dominant Targets of IGHV1-69-encoded Antibodies Expressed by CLL B Cells
We examined recombinant antibodies from each of four previously identified subsets of IGHV1-69-encoded Ig heavy chains, designated as CLL69A, -B, -C, and -D, and tested them for binding to OxLDL and antigens modified with simple or complex MDA type epitopes. For this, we prepared simple, nonfluorescent MDA adducts (MDA-LDL and MDA-BSA) as well as complex, highly fluorescent MDA adducts, termed MAA (malondialdehyde-acetaldehyde adducts, MAA-LDL and MAA-BSA). Note that the MDA-modified preparations still contain a small number of fluorescent MAA adducts, and in turn, the MAAmodified preparations contain small numbers of simple MDA epitopes. Fig. 1A shows results from a direct Ab-binding assay of the four recombinant IGHV1-69-encoded rAbs, as well as control Abs, to the various antigens. Each of the four IGHV69-encoded rAbs bound predominantly to the highly fluorescent MAA epitopes. Although each of the four IGHV1-69 rAbs bound to MAA and MDA epitopes, CLL69C rAb had by far the greatest binding activity, for example, binding to MAA-epitopes (MAA-LDL and MAA-BSA) eight-fold higher than that of any of the other CLL69 subsets.
Among the various antigens tested, there was a clear preference for binding to the more complex MAA epitopes. Specifically, CLL69C rAb bound avidly to MAA-LDL and MAA-BSA, but also had lower binding to MDA-LDL and MDA-BSA, and to even a lesser degree to Cu-OxLDL, but did not bind to non-oxidized (native) LDL or BSA (Fig. 1A). CLL69A rAb, showed the next highest binding reactivity, although at much lower levels, having similar binding reactivity for MAA-LDL, MAA-BSA, or MDA-LDL, but not native LDL or BSA. CLL69B and CLL69D rAbs had minimal binding activity for each of a variety of oxidative epitopes on modified LDL or BSA. Both CLL69A and CLL69C exhibited dose-dependent binding to MAA-LDL ( Figure S1, left panel) and at lower levels to MDA-LDL ( Figure S1, right panel).
In all assays, control rAbs with Ig heavy chains encoded by IGHV3-21, or samples without rAb, did not bind to any of the antigens. The specificity of the binding of CLL69C rAb for MDA/MAA epitopes was verified in competition immunoassays in which binding to plated antigen was assessed in the presence of increasing concentration of soluble competitor antigen (Fig. 1B). The binding of CLL69C rAb to MAA-LDL (left panel) or to MAA-BSA (middle panel) was specifically competed only by MAA-epitopes (MAA-LDL or MAA-BSA), but not MDA-epitopes (MDA-LDL or MDA-BSA) or OxLDL, which is more enriched with oxidized phospholipid epitopes. Additionally, the binding of CLL69C rAb to MDA-LDL (right panel), which contains a low content of MAA epitopes, was competed mainly by antigens enriched in MAA epitopes (MAA-LDL or MAA-BSA). (It should be noted that the Y-axis in these competition data represent the percent competition of the competing antigen to inhibit binding of CLL69C to the indicated antigen. The CLL69C rAb had absolute binding activity for MDA-LDL that was much less than that for MAA-LDL, as shown in Fig. 1A). Collectively, these data demonstrate that CLL69C rAb binds to MAA epitopes, which are greatly enriched in MAA-modified proteins, and present to only a minor degree in MDA-modified preparations.
The Light Chain of CLL69C Recombinant Antibody Contributes to MAA-adduct Binding IGHV1-69 subgroups contain HCDR3 with strikingly homologous amino acid sequences and, in many cases, these HCDR3 are associated with nearly identical Ig light chains, thereby forming BCRs that are identical or nearly-identical in unrelated patients. This suggests recognition of common epitopes in this subset. To examine the contribution of Ig light chains to the binding activity of CLL69C-encoded rAb for MAA epitopes, we assessed the relative binding activity for MAA-epitopes of rAb comprised of Ig heavy chains of CLL69C paired with non-native pairs of Ig light chains from CLL69A, B, or D. The results revealed that the recombinant CLL69C Ig heavy chain paired with its native IGLV3-9-encoded Ig light chain bound MAAepitopes more effectively than the CLL69C IgH paired with nonnative Ig light chains of CLL69A, B, or D (Fig. 2, left panel). However, CLL69A Ig heavy chains paired with the CLL69C IgL chain (IGLV3-9), designated CLL69A/C, exhibited three-to fivefold higher binding to the MAA-epitopes over the parental CLL69A/A recombinant Ab (Fig. 2, right panel). These observa-tions suggest that the Ig light chain of CLL69C also contributes to the binding activity of rAb for MAA-epitopes.

MAA-mimotopes are Recognized by CLL69 Abs
We recently defined two short-chain peptide mimotopes for MAA-epitopes (P1 and P2) that were identified from phage peptide libraries, one consisting of a 12-mer linear peptide (P1-HSWTNSWMATFL), and the other being a cysteine-constrained heptamer cyclic peptide (P2-ACNNSNMPLC) (Fig. 3A). Each of these mimotopes were selected because of their ability to bind LR04, an MAA-specific mAb cloned in our lab, as recently reported [20]. We therefore tested whether the CLL69C rAb was also able to recognize these mimotopes. As shown in Fig. 3B, CLL69C rAb bound readily to P1 in a dose dependent manner, and to a more limited extent to P2, but not to a control scrambled peptide. As these peptides are small, and binding to microtiter wells might distort their conformation, they were biotinylated and bound to avidin-coated wells. Competition immunoassays demonstrated that binding of CLL69C rAb to P1 was effectively competed by increasing concentrations of soluble MAA-BSA and P1 peptide (Fig. 3C), but not by unmodified BSA or control peptide, confirming the high specificity of CLL69C rAb for the P1 MAA-mimotope.

Molecular Analysis of IGHV1-69 Homologs from OSE Selected Umbilical Cord Fab Phage Library
IgM in newborn cord-blood are thought to best represent innate NAbs in humans. We have shown that OSE epitopes are a major target of the IgM in newborn cord blood, and that in particular, MAA-epitopes might account for up to 15% of all such IgM [15]. Therefore, we generated a human Fab phage display library using lymphocytes isolated from newborn cord-blood that would be enriched for innate NAbs binding to OSE. To investigate if the CLL69 subset gene homolog could be enriched from this library, we panned the umbilical cord Fab phage display library for 4rounds with OSE (MAA-BSA and MDA-LDL), perhaps mimicking the natural selection of CLL69 BCR by neo-self-antigen epitopes. To isolate IGHV1-69-encoded heavy chains, the phages from the 4 th -round MAA-BSA selected phage library were pooled and PCR amplified, using an oligonucleotide 59-primer specific for the CDR2 of IGHV1-69 and a consensus 39-primer of IGHJ6. Six unique clones were isolated and sequenced (Table 1), and two of them, UCL2 and UCL3, had high homology to CLL69C and CLL69B, respectively ( Table 1). The other four clones were less well matched to any of the IGHV1-69-encoded Ig heavy chains that belong to subsets CLL69 A-D. UCL2 was 98% homologous to the germline IGVH1-69 gene, and best aligned to the stereotypic CLL69C HCDR3 sequence. The HCDR3 of UCL2 was encoded by the IGHV1-69, IGHD3-3, and IGHJ6 genes, with N insertions at both IGHV-IGHD and IGHD-IGHJ junctions, but is two amino acids shorter at the N1 insertion compared to CLL69C ( Table 1). The UCL3 heavy chain was most homologous to the CLL69B HCDR3 sequence, as UCL3 and CLL69B both have HCDR3 encoded by IGHD2-2 and IGHJ6 and the amino acid motif DIVVVPAA encoded by the third reading frame of IGHD2-2 (Table 1). Thus, the unmutated prototypic CLL69 ancestors selected from the primary BCR repertoire of umbilical cord Fab library were similar to those of CLL69C expressed by leukemia B cells.

Analysis of HCDR3 Rearrangement of a Fab Clone from Phage Display Library
The human umbilical cord Fab phage libraries pre-selected from 4th-round panning against MAA-BSA epitopes -both kappa and lambda-were further panned for binding to mAb G6 [25,28], a murine anti-idiotypic mAb that recognizes unmutated IgH encoded by IGHV1-69. The nucleotide sequences of the IgH and IgL of one Fab clone that was isolated, designated UL10, were found to be nearly identical to the heavy chain of CLL69C (Fig. 4). The Ig heavy chain of UL10 is unmutated and encoded by IGHV1-69 (Fig. 4A), with a 20 amino acid long HCDR3 that is identical to UCL2, and is enriched in Tyr (Y), Gly (G), and Ser (S), prototypic of the HCDR3 of the unmutated CLL69C subset found expressed by CLL B cells. The HCDR3 includes nucleotide insertions both in the IGHV-IGHD junction (1 palindromic and 3 nucleotides) and IGHD-IGHJ junction (3 nucleotides) ( Table 1). The IGHD3-3 gene and IGHJ6 gene are unmutated from the germline gene sequences. The finding of a CLL69C progeny in an OSE-selected Fab library isolated from newborns is consistent with the hypothesis that this Ig might be selected in vivo for binding to endogenous OSE.

Expression of Active Fab Ab and Light Chain Shuffling Study
The UL10 Fab clone was expressed in E. coli BL21 (DE3) cultures with 39-terminal His 6 -and HA-double tags, and purified by affinity chromatography on a Ni 2+ -NTA-resin column and an additional step of anti-HA filtration chromatography. Immunoblots of SDS-PAGE of purified fractions under non-reducing conditions probed with anti-HA-tag Ab showed the near homogeneity of the Fab Ab fragment (Fig. 5, left panel). The purified UL10 Fab was soluble and functionally active, as it displayed the same pattern of binding reactivity to MAA epitopes as CLL69C rAb (data not shown).
Due to the nature of the combinatorial approach, light chain usage in combinatorial Fab clones was presumably random. The IgH and IgL chains of UL10 present in the Fab library may or may not have been originally paired in the human fetal IgM repertoire. To determine whether UL10 could form a functional anti-MAA Fab with alternative light chains, the UL10 IgL chain was exchanged with CLL69C light chain and evaluated for binding to MAA-LDL. Both the originally isolated UL10 (with IGLV2-14) and UL10 (paired with IGLV3-9 L chain of CLL69C) bound indistinguishably to the modified antigens, and specifically to MAA epitopes (Fig. 5, right panel). This demonstrates that Ig heavy chain of the CLL69C homolog Ab fragment (Fab) can also be paired with stereotypic CLL69C IgL and retain binding reactivity for the MAA-epitope.

CLL69 Abs Bound to OSE on Apoptotic Cells
Oxidation-specific-epitopes are not only found in OxLDL, but are also prominent on apoptotic cells. We and others have shown the presence of a variety of OSE on apoptotic cells including the presence of oxidized phospholipids, and various MDA type epitopes including MDA and MAA [15,29]. Indeed, all investigated murine and human NAbs display binding to apoptotic cells, particularly in late stages. Therefore, the binding of CLL69 rAb to apoptotic Jurkat cells and murine thymocytes was investigated using flow cytometry. Staining of Annexin V-PE and 7-AAD was used to separate apoptotic from non-apoptotic cells during flow cytometry. CLL69 rAb did not bind to viable cells with low Annexin V/7-AAD staining (Fig. 6A, Q3), but displayed increased binding to apoptotic thymocytes that had high Annexin V/7-AAD staining (late apoptotic cells, Fig. 6A, Q2). Figure 6A also shows that MAA-epitope specific CLL69C rAb bound more strongly to apoptotic thymocytes induced by PMA than other CLL69 rAbs. The specificity was verified by addition of 100 mg/mL MAA-BSA into the incubation medium, which almost totally abolished the CLL69C rAb binding to the apoptotic cells (data not shown). In addition, UV light exposure to induce apoptosis in Jurkat T-cells also resulted in similar binding of CLL69C (data not shown).
The flow cytometric analysis was confirmed by immunofluorescence microscopy, where CLL69C rAb bound to permeabilized late apoptotic cells (Fig. 6B, left panel). Using deconvolution microscopy, we demonstrated intense intracellular CLL69C rAb binding (FITC, green color) inside cells that had undergone apoptosis (fragmented dense nucleus visualized with blue Hoechst dye) and not to cells that had intact nucleus. No binding was observed with a control CLL rAb to the same cells (Fig. 6B, middle  and right panel). These results support the hypothesis that OSE from dying cells, or their released apoptotic bodies or microparticles, could be commonly prevalent antigens leading to expansion of CLL69C B cells.

Inhibition of Binding of MAA-LDL to Macrophages by CLL69C Abs
We previously demonstrated that many OSE-NAbs could bind to OxLDL and prevent binding and uptake of OxLDL by macrophages. Indeed, elevation of titers of certain OSE-Nabs, such as E06, was shown to be atheroprotective [30]. To evaluate if CLL69C rAb or UL10 Fab have functions similar to IgM NAbs, we examined the ability of these Abs to inhibit the binding of biotinylated MAA-LDL to macrophages. In prior studies, we showed that MAA-LDL binds specifically to macrophage scavenger receptors [15]. Biotinylated MAA-LDL was added to J774 macrophages in the absence or presence of increasing concentrations of CLL69C rAb, UL10 Fab, or control Ab, and the extent of binding was determined (Fig. 6C). Both CLL69C rAb and UL10 Fab competed for MAA-LDL binding in a dose dependent manner, while neither CLL69A or control IGHVH3-21-encoded rAb bound, demonstrating the specificity of CLL69C -derived rAbs to the MAA-LDL adducts (Fig. 6C).

CLL69 Abs Recognized OSE in Atherosclerotic Lesions
As we and others [18] have shown that MAA epitopes are enriched in atherosclerotic lesions, we examined if CLL69C rAb could immunostain such lesions. CLL69C rAb strongly immunostained atherosclerotic lesions from human carotid endarterectomy (CEA) specimens (Fig. 6D) or WHHL rabbit aortas ( Figure S2). In particular, the necrotic cores of the lesions were strongly stained with CLL69C rAb, but not control Ab ( Figure S2), similar to observations obtained in our lab with the MAA-specific NAb LRO4 (data not shown).

Discussion
In this study we analyzed the binding reactivity of several CLL derived sterotypic IGHV1-69-encoded rAb to multiple oxidation specific epitopes, which are a major target of innate NAbs. We found that IGHV1-69-encoded rAb, particularly CLL69C or CLL69A, bound to OSE, and more specifically to the immunodominant OSE adduct MAA, which is found on apoptotic cells, inflammatory tissues, or atherosclerotic lesions. CLL69C rAb also reacted specifically with MAA-specific peptide mimotopes. Light chain shuffling indicated that non-stochastically paired CLL69C IgL encoded by IGLV3-9 contributes to the antigen binding of CLL69C. Furthermore, nearly identical CLL69C IgH were isolated from an MAA-enriched umbilical cord IgM phage displayed Fab library, indicating the presence of these conserved IgH in the early, developing B cell repertoire.
Molecular mimicry between microbial pathogens and neo-self Ag has been suggested to be a critical contributor to the activation of autoreactive B cells [31,32]. The IGHV1-69 gene has also been shown to be preferentially used by Ig heavy chains of the Ab generated in a number of viral and bacterial infections and autoimmune disorders, such as neutralizing antibodies to the HIV gp120 glycoprotein [33], and hemagglutinin of influenza subtypes [34], as well as in anti-DNA and cardiolipin autoantibodies from patients with systemic lupus erythematosus [22,35]. In concert with other immunomodulatory mechanisms, such as B cell activation and recurrent stimulation with autoantigens that display molecular mimicry with exogenous pathogens [36,37], these immune responses may escape regulation, leading to the formation of pathogenic autoantibodies, suggesting that common antigenic stimulation could cause the unconstrained expansion of activated IGHV1-69-expressing B cells.
The rAbs that belong to the CLL69A subgroup (IGHV1-69/ IGKV3-20) are virtually identical to a natural Ab of IgM IGKV3-20 class with anti-cardiolipin/rheumatoid factor (RF factor) activity and low-affinity for a variety of self-antigens (RF activity and bind to myoglobulin, actin, and ssDNA) [38]. IGHV1-69/ IGKV3-20 expressing Ig are also over-represented among natural IgM Abs that cause mixed cryoglobulinemia associated with hepatitis C virus infection [39]. The CLL69C Ab resembles the BCR from a group of CLL cases (CLL22, CLL17, and CLL72) using the HCDR3 rearrangement (IGHV1-69/IGHD3-3/IGHJ6) and IGLV3-9-encoded light chain reported previously [40]. Among 21 cases that express the CLL69C HCDR3 motif, four were identical and 17 others had marked CDR3 homology in both IgH and IgL chains, which might reflect selection for specific structural motifs that facilitate antigen binding. The remarkable similarity for the known hypervariable HCDR3 regions within multiple CLL patients strongly supports the view that particular antigen reactivity is the selective force. The expression of such conserved BCRs with restricted HCDR3 in CLL disease suggests a potential role for antigen stimulation in the development and/or progression of CLL.
Oxidation-specific epitopes represent prominent examples of oxidative, stress-induced altered self. These OSE are generated ubiquitously as a consequence of lipid peroxidation during many physiological and pathological situations, including leprosy, diabetic nephropathy, hepatosteatosis, various CNS diseases (including multiple sclerosis and Alzheimer), rheumatoid arthritis, and carotid, femoral, or coronary atherosclerosis [14]. OSE are also prominently generated in inflammatory viral and bacterial diseases, and may share molecular mimicry with epitopes on pathogens [14]. Importantly, trillions of apoptotic cells are generated daily and OSE are prominently found on the membranes of apoptotic cells, shed apoptotic bodies and microparticles.
Among the many OSE generated, oxidized phosphocholine (PC) phospholipids that display the PC epitope, which shares molecular identity with the PC of pathogens, is a common target of many NAbs, such as E06, which we have extensively characterized, as well as CLL BCRs [35,36]. Malondialdehyde is an even more ubiquitous end product of lipid peroxidation and readily forms both simple and complex adducts with proteins and other lipids. Among these, we have shown that as a class, such OSE are a major target of innate NAbs. Because many CLL BCRs display gene usage consistent with NAbs, it is not surprising then that many such BCRs bind to OSE. Indeed, several recent reports document that OSE, such as the PC of OxLDL and bacteria, and MDA, are common target antigens to which the BCRs of many CLL might bind [35,36].
Among different MDA-type adducts, we and others have shown that MAA epitopes are immunodominant, being detected in a variety of inflammatory tissues, including alcoholic hepatitis, atherosclerotic aortic lesions, and apoptotic cells [15,16]. Remarkably, we have recently shown that MAA epitopes are the target of , 15% of all IgM NAbs in mice and in human newborn cordblood [15]. Here we demonstrate that CLL69C specifically recognizes MAA epitopes, as shown by direct binding assays (Fig. 1A) as well as in competition immunoassays (Fig. 1B). Furthermore, it also had the biological property of inhibiting the binding of MAA-LDL to macrophages (Fig. 6C). CLL69C also specifically immunostained apoptotic cells (Fig. 6B) and both human and rabbit atherosclerotic tissue (Fig. 6D, Fig. S2). Thus, it appears to have all of the immunological binding properties of numerous OSE NAbs we have studied. These observations suggest the possibility that the continual generation of these ubiquitous epitopes throughout life contributed to the positive selection of CLL B-cells that express Ig with such specificities. Furthermore, light-chain shuffling tests (Fig. 2) indicated that both the CLL69C Ig heavy and Ig light chains contributed to the binding activity of apoptotic (Q4, Annexin-V + /7-AAD 2 ) and late apoptotic cells (Q2, Annexin-V + /7-AAD + ). Histogram panels Q3 (bottom left), Q4 (bottom right) and Q2 (upper right) represent rAb staining of viable cells, early apoptotic cells, and late apoptotic cells, respectively. Relative cell fluorescence of rAbs CLL69 A-D and IGHV3-21 control rAb are indicted by colored lines, and staining with the secondary Ab alone is shown in grey. (B) Immunofluorescence microscopy of CLL69C rAb binding to apoptotic cells. Deconvolution microscopy showing the binding of CLL69C rAb to late apoptotic Jurkat cells (FITC green color, the cell on the left panel) with dense fragmented nucleus detected by Hoechst staining (blue color), and apoptotic cells detected by PE-Annexin-V (red color), but not to a cell with intact nucleus (Panel A). The vector control and secondary Ab only (anti-IgG1-FITC) do not bind the apoptotic cells (panel B and C, respectively). (C) Inhibition of MAA-LDL binding to macrophage scavenger receptors by CLL69Ab. Competition assays for the inhibition of biotinylated-MAA-LDL binding to macrophage J774 by CLL69C rAb, UL10 Fab, or an irrelevant control VH3-21 rAb, as indicated. A fixed and limiting amount of biotin-MAA-LDL (5 mg/ml) was added to J774 macrophages in the absence or presence of increasing concentrations of indicated competitors. Extent of binding was determined in RLU/100 msec as described for chemiluminescent ELISA assays. Data shown represent the ratio MAA-LDL binding in the presence or absence of competitors (B/B 0 ) as described in legend to Fig. 1B. Results are representative of three independent experiments, each point determined in triplicate. (D) Immunohistochemical staining of human carotid endarterectomy (CEA) specimens. Roughly parallel sections of human carotid endarterectomy tissue were stained with rAbs of CLL69C (panel C), CLL69A (panel B), or a secondary Ab alone (panel A). MAA-epitopes recognized by CLL69C or CLL69A are indicated by red color. doi:10.1371/journal.pone.0065203.g006 rAb for MAA epitopes. Indeed, in a recent report, Catera et al. [36] also noted that CLL BCRs with heavy chains that had similar HCDR3 gene usage (IGHV1-69/IGHD3-03/IGHJ6) but with different light chains, also bound to apoptotic cells, and had weak binding to MDA-BSA, but they did not test binding to MAA.
In support of the hypothesis that CLL69C was selected by ongoing MAA-epitope exposure, we demonstrated the presence in a human fetal Fab library of unmutated ancestor IGHV1-69 germline domains (CLL69C). We utilized PCR and anti-idiotypic mAb to IGHV1-69 to investigate the ontology of CLL69C gene lineage maturation and clonal expansion from the fetal BCR repertoire. The UCL2, UCL3, and UL10 clones were isolated from an MAA-enriched phage library, and were found encoded by unmutated IGHV1-69 germline genes (CLL69). We produced a Fab clone with the UL10 IgH chain paired with the CLL69C light chain to generate a soluble Fab Ab and found that this Fab also bound prominently to MAA epitopes (Fig. 5). Further evidence for the existence of CLL69C-like heavy chains of normal B cells is provided in a study that analyzed the nucleotide sequences and primary molecular structure of 143 IGHV1-69-encoded IgH that were derived from the B cells of three healthy adult donors [13]. They found that 22 (15%) of the IgH could be classified into a previously identified HCDR3 subgroup, including four that were assigned to the CLL69C analogous subgroup 7. No IgH belonging to the CLL69-A subgroup were identified, as the analysis was specific for identifying IgH with longer than average HCDR3encoded by IGHJ6. In aggregate, these data further advance the hypothesis that host MAA-epitopes could drive clonal expansion of stereotypic subsets of CLL69C B cells with optimal binding for MAA. Presumably these continually proliferating B cells subsequently escape vital checkpoint regulation, resulting in the unregulated clonal expansion leading to CLL [41,42,43].
As noted above, MAA-epitopes have been identified as immunodominant epitopes of MDA-modifications, and that there are high-titered MAA-specific IgG and IgM Abs in human plasma. We recently identified small peptide mimotopes that mimic MAA-epitopes in MAA-LDL, which in turn were recognized by LR04, an MAA-specific monoclonal Ab [20]. Similar to LRO4, we showed that CLL69C bound to these MAA-mimotopes, and in particular to the P1 mimotope in a dosedependent manner (Fig. 3B), and that this binding was efficiently inhibited by increasing concentrations of soluble MAA-BSA (Fig. 3C). Thus, the MAA mimotope P1 might have potential in diagnostic applications to identify MAA-specific Abs, such as CLL69C. The availability and reproducibility of these small peptide mimotopes could facilitate the development of standardized clinical assays, allowing the rapid identification of such BCRs on CLL B cells. The CLL69C gene analyses and MAA-binding levels may be an important prognostic indicator, along with other biologic markers, for prediction of CLL disease outcome.